Sede Azogues - Medicina
URI permanente para esta comunidadhttps://dspace.ucacue.edu.ec/handle/ucacue/88
Examinar
Examinando Sede Azogues - Medicina por Asesores "Buenaño Rodríguez, Christian Eduardo"
Mostrando 1 - 5 de 5
- Resultados por página
- Opciones de ordenación
Ítem Acceso Abierto Abordaje terapéutico de cáncer de próstata, en enfermedad metastásica sensible a la castración. Revisión Sistemática(Universidad Católica de Cuenca., 2025) Salas Olave, Jhenniffer Andrea; Buenaño Rodríguez, Christian Eduardo; 0926943655Background: Prostate cancer represents a significant public health concern among the male population due to its high incidence, accounting for 9.8% of cases, and a global mortality rate of 7.7%. Accordingly, treatment strategies vary depending on the extent of disease progression. Objective: To analyze the therapeutic approach to metastatic castrate-sensitive prostate cancer (mCSPC) through a systematic review. Methodology: A systematic review was conducted following the PRISMA 2020 guidelines. Scientific articles were retrieved from PubMed, Springer, Taylor & Francis, and Scopus databases. PICO strategies were applied for screening. Results: A total of 24 scientific articles, including clinical trials, case reports, as well as prospective and retrospective studies, were reviewed to identify effective therapies for castrate-sensitive prostate cancer. Discussion: Several limitations were encountered, such as restricted access to some articles due to financial constraints. Nevertheless, the available evidence supports the recommendation of androgen deprivation therapy (ADT) combined with Abiraterone acetate, which significantly improves survival in patients with mCSPC and is therefore considered the standard of care for this patient population. Conclusion: The recommended therapeutic approach for metastatic castrate-sensitive prostate cancer involves combining new antiandrogens such as Abiraterone, Enzalutamide, and Apalutamide with ADT, as this strategy enhances overall survival compared to ADT alone. Keywords: therapeutics, castration, prostatic neoplasms, hormonal therapy, metastatic neoplasmsÍtem Acceso Abierto Actualización del manejo del carcinoma ductal infiltrante luminal A en pacientes con enfermedad metastásica. Revisión Sistemática(Universidad Católica de Cuenca., 2025) Campoverde Martínez, Nicole Guadalupe; Buenaño Rodríguez, Christian Eduardo; 0350009916Background: Luminal invasive ductal carcinoma A presents HR to progesterone and estrogen, with the absence of HER2 and with the cell multiplication marker Ki67 below 14%. These particularities show a good prognosis, evolution, and prosperous response to hormone therapy (1,2). General Objective: To investigate the current management of patients with metastatic disease. Specific Objectives: To detail cyclin inhibitor drugs, to analyze safety considering response rate, overall survival, and side effects, and to compare efficacy and impact in relation to other therapies. Research Question: What is the management of luminal infiltrating ductal carcinoma A in patients with metastatic disease? Methods: Databases were analyzed to compile information, being SciELO, Scopus, and PubMed, considering observational, cost-effectiveness, randomized, descriptive, and meta-analysis studies of original articles on patients with advanced disease published locally and internationally, with a range of less than five years and available mainly in Spanish and English, in full text and open access. Results: Twenty-five scientific articles corresponding to the databases mentioned were analyzed; they were referenced with their title, author, year, objectives, the total sample size, and the results of these studies. Conclusions: The cyclin inhibitors Ribociclib, Palbociclib, and Abemaciclib, employed in the management of this neoplasm, are beneficial in terms of efficacy and tolerability; they present advantages by specifically targeting checkpoints in the cell period interfering with cancer cell proliferation. Keywords: carcinoma, breast, luminal A, metastasis, cyclin inhibitorsÍtem Acceso Abierto Detección temprana de cáncer gástrico utilizando nuevas técnicas endoscópicas. Revisión sistemática(Universidad Católica de Cuenca., 2024) Jimbo González, Wendy Dayana; Buenaño Rodríguez, Christian Eduardo; 0302678719Gastric cancer (GC)is one of the most common cancers with high mortality rates worldwide, so early detection is crucial to improve survival rates, which can reach 70% if the cancer is detected when it is still limited to the superficial layers of the stomach. Endoscopy plays a vital role in the early identification of gastric lesions, enabling direct visualization of the stomach lining and detecting abnormalities before the cancer progresses. This tool has effectively reduced mortality risk by enabling timely, less invasive interventions. This systematic review evaluates advances in endoscopic techniques, focusing on innovations that enhance early GC detection and improve patient outcomes. Studies published between 2019 and 2024 that reported new endoscopic techniques for early GC detection were included for analysis using the PubMed and Scopus databases. Forty-seven studies met the eligibility criteria and were analyzed in full text. This systematic review describes the most recent advances in white light endoscopy, chromoendoscopy, endoscopic ultrasound, confocal endomicroscopy, and serological biomarkers. In conclusion, these innovative techniques, together with advanced technologies, improve the quality of the results and, when combined with artificial intelligence, facilitate real-time histopathological analysis, obtaining a more accurate characterization of early-stage GC tumors. Keywords: Gastric cancer, endoscopy, diagnostics, innovationÍtem Acceso Abierto Eficacia del Tofacitinib y Baricitinib en el tratamiento de artritis reumatoide: revisión sistemática(Universidad Católica de Cuenca., 2025) Díaz Carrera, Mizhell Tatiana; Buenaño Rodríguez, Christian Eduardo; 0302633664Introduction: Rheumatoid arthritis is a chronic condition that significantly impacts patients’ quality of life. The development of Janus kinase inhibitors, such as tofacitinib and baricitinib, represents an effective therapeutic alternative. However, it is necessary to analyze the available evidence to determine their efficacy and safety. Methods: A systematic literature review was conducted from January 2010 to June 2024, following PRISMA guidelines. The search was performed in PubMed, Scopus, Cochrane Library, and ClinicalTrials.gov, using MeSH terms related to tofacitinib, baricitinib, and rheumatoid arthritis. Randomized clinical trials, comparative studies, and systematic reviews that evaluated clinical efficacy, as expressed by remission, DAS28, and ACR responses, were included. Quality assessment was performed using NHLBI criteria, and risk of bias was assessed using the RoB 2 tool. Results: A total of 45 studies were identified, of which 34 were selected after applying eligibility criteria. Finally, 17 studies published between 2010 and 2024 met the specific objectives, highlighting adequate methodological quality and a low risk of bias in key domains such as random sequence generation and intervention blinding. Relevant outcomes included significant clinical response rates (ACR20) and sustained improvements in the DAS28 scores; however, limitations remain regarding the clarity of adverse event reporting and loss to follow-up. Conclusion: Both tofacitinib and baricitinib are effective therapeutic alternatives for the management of rheumatoid arthritis, with consistent evidence of clinical improvement in standardized parameters.Ítem Acceso Abierto Propuestas de intervención en cáncer de riñón, principales técnicas y métodos utilizados en el tratamiento del cáncer de células renales. Revisión Sistemática.(Universidad Católica de Cuenca., 2025) Chacon Gahona, Christopher Jeanpierre; Buenaño Rodríguez, Christian Eduardo; 0105322408In recent years, the incidence of kidney cancer has progressively increased worldwide, particularly renal cell carcinoma, the most common form of this neoplasm. Risk factors such as smoking, obesity, and hypertension have been identified, in addition to incidental diagnoses through imaging techniques. Despite advancements in targeted therapies and immunotherapy, nephrectomy remains the primary treatment. The evolution of surgical and therapeutic methods has necessitated an analysis of the main techniques employed to enhance intervention proposals for treating renal cancer. OBJECTIVE: To analyze the primary techniques and methods used in the treatment of renal cell carcinoma. METHODOLOGY: This is a descriptive, retrospective, systematic review with a mixed approach, as it collected, analyzed, and described information detailed in scientific articles related to the treatment of renal cell carcinoma. RESULTS: In the past decade, a notable increase in research on kidney cancer has been observed. Several studies have determined that radical nephrectomy is the primary technique for addressing this pathology, especially in advanced stages. They also highlight the significance of pharmacological treatments in the early stages. CONCLUSIONS: The systematic review of research on kidney cancer reveals a significant evolution in the understanding and management of this disease. Keywords: cancer, kidney, nephrectomy, sunitinib, axitinib
